ACREME Webinar: Evaluation of a pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs and The cost-effectiveness of tafenoquine following G6PD screening in Brazil: a transmission model
The Australian Centre of Research Excellence in Malaria Elimination (ACREME) is happy to invite you to their next fortnightly webinar on “Evaluation of a pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs” and “The cost-effectiveness of tafenoquine following G6PD screening in Brazil: a transmission model analysis“.
Evaluation of a pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs with Professor Julie Simpson.
- The unrelenting rise of multidrug resistant malaria demands the continuous development of novel antimalarial compounds from preclinical studies in human volunteers to Phase 3 clinical trials in patients. This presentation will present a simulation study performed to assess the utility of a Bayesian hierarchical mechanistic pharmacokinetic-pharmacodynamic(PK-PD) model for predicting parasite-time profiles for a Phase 2 study of a new antimalarial drug, cipargamin.
The cost-effectiveness of tafenoquine following G6PD screening in Brazil: a transmission model analysis with Dr Angela Devine.
- While results from a Plasmodium vivax dynamic model have shown the potential impact of quantitative glucose-6-phosphate dehydrogenase (G6PD) test-and-treat strategies using tafenoquine for radical cure on cases averted, the cost-effectiveness has not been previous explored using a transmission model framework. Here, we explore the impact on the overall cost-effectiveness in Brazil under four scenarios. Our results provide strong evidence that tafenoquine prescribed after a quantitative G6PD test is highly likely to be cost-effective in Brazil.
Date: Wednesday, October 12, 2022.
Time: 5:00 am – 6:00 am CEST.
If you’d like to attend, please register at this link.
Read more here.
